Clinical course, management and outcomes of COVID-19 in HIV-infected renal transplant recipients: A case series
Laurie Bertels1, Kathryn Manning1, Andrew D. Redd2,3,4, Tinus Du Toit1, Zunaid Barday5, Elmi Muller1,6.
1Department of Surgery, University of Cape Town, Faculty of Health Sciences, Groote Schuur Hospital, Cape Town, South Africa; 2Division of Intramural Research, NIAID, NIH, Bethesda, MD, United States; 3Department of Medicine, Johns Hopkins University, Baltimore, MD, United States; 4Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; 5Department of Medicine, University of Cape Town, Faculty of Health Sciences, Groote Schuur Hospital, Cape Town, South Africa; 6Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
Background: HIV-infected kidney transplant recipients with COVID-19 are at increased risk of acute illness and death owing to their underlying comorbidities and chronic immunosuppression.
Objectives: To describe the incidence, clinical presentation and course of COVID-19, vaccination status, and SARS-CoV-2 antibody positivity rate among HIV-infected-to-HIV-infected kidney transplant recipients in South Africa (SA).
Methods: This retrospective study reports on rates of SARS-CoV-2 infection, COVID-19 and mortality among SA HIV-infected kidney transplant recipients who received organs from HIV-infected donors (HIV positive to HIV positive), before and after vaccination. Patient demographics, clinical presentation, course, management and disease outcomes were analysed. Antibody serology tests were performed between May and September 2022.
Results: Among 39 HIV-positive-to-HIV-positive transplant recipients, 11 cases of COVID-19 were diagnosed from March 2020 to September 2022. Six patients (55%) required hospitalisation, of whom 3 were admitted to a high-care unit or intensive care unit. Two patients required mechanical ventilation, and 2 received acute dialysis. One patient was declined access to intensive care. Four patients (10%) died of COVID-19 pneumonia. All the COVID-19-positive patients had at least one comorbidity. Vaccination data were available for 24 patients, of whom 5 had refused SARS-CoV-2 vaccination. SARS-CoV-2 antibody data were available for 20 patients; 4 vaccinated patients had a negative nucleocapsid protein antibody test and a positive spike protein antibody test, suggesting vaccination-acquired immunity. The remaining 16 patients demonstrated immunity that was probably due to COVID infection, and of these, 14 were also vaccinated. Of the 11 COVID-19 cases, only 1 was observed after vaccination.
Conclusion: In our case series, ~10% of the HIV-positive-to-HIV-positive transplant recipients died of COVID-19 pneumonia. This mortality rate appears higher than figures reported in other transplant cohorts. However, it is likely that the actual number of cases of SARS-CoV-2 infection was much higher, as the study only included polymerase chain reaction-confirmed cases. It remains unclear whether HIV infection, transplant or the combination of the two drives poorer outcomes, and larger studies adjusting for important demographic and biological factors may isolate these effects.
